The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Initial efficacy and biomarker analysis of a phase 1b study targeting IL-1β and PD-1 with chemotherapy in metastatic pancreatic cancer (PanCAN-SR1).
 
Paul Eliezer Oberstein
Consulting or Advisory Role - AstraZeneca; Delcath Systems; Merck; QED Therapeutics; Rubius Therapeutics
Speakers' Bureau - AstraZeneca
Research Funding - Arcus Biosciences (Inst); Merck (Inst); Rafael Pharmaceuticals (Inst); Roche/Genentech (Inst)
Expert Testimony - Ipsen
Travel, Accommodations, Expenses - Merck
 
Osama E. Rahma
Employment - AstraZeneca/MedImmune
 
Nina Beri
No Relationships to Disclose
 
Amy C. Stoll-D'Astice
Stock and Other Ownership Interests - Abbott Laboratories; Bristol-Myers Squibb/Celgene (I); Cerner (I); Cigna (I); Gilead Sciences (I); Lilly (I); Moderna Therapeutics; Regeneron
Other Relationship - Fibrogen (Inst); Novartis (Inst); Tyme Inc. (Inst)
 
Anne-Marie Duliege
Stock and Other Ownership Interests - Abbvie; Amgen; Exelixis; Gilead Sciences; Jazz Pharmaceuticals; Regeneron
Consulting or Advisory Role - Federation Bio
 
Emily Kawaler
No Relationships to Disclose
 
Igor Dolgalev
No Relationships to Disclose
 
Gregor Werba
No Relationships to Disclose
 
Victoire Cardot-Ruffino
No Relationships to Disclose
 
Naïma Böllenrücher
No Relationships to Disclose
 
Saloney Nazeer
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Matthew Squires
Employment - Novartis Pharmaceuticals UK Ltd.
Stock and Other Ownership Interests - Novartis
Patents, Royalties, Other Intellectual Property - Novartis
 
Dafna Bar-Sagi
Patents, Royalties, Other Intellectual Property - Dr. Bar-Sagi is Co inventor on US Patents 10,221,215 and 8,987,412 which are under a license to Inthera. Under this license Dr. Bar-Sagi will receive a portion of annual license maintenance payments. NYU holds equity in Inthera valued at approximately $16
 
Brian M. Wolpin
Honoraria - Celgene; G1 Therapeutics
Consulting or Advisory Role - BioLineRx; Celgene; G1 Therapeutics; Genentech; GRAIL; GRAIL
Research Funding - Celgene; Lilly
 
Stephanie Dougan
Leadership - Kojin Therapeutics; Neoleukin Therapeutics (I)
Stock and Other Ownership Interests - Kojin Therapeutics
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - Bristol-Myers Squibb; Lilly; Novartis Institutes for BioMedical Research
Patents, Royalties, Other Intellectual Property - Patent pending for an HSV immunotherapeutic delivery vector
 
Diane M. Simeone
Consulting or Advisory Role - Celgene
Research Funding - Abbvie
Patents, Royalties, Other Intellectual Property - small royalties for my patent on pancreatic cancer stem cells also I receive an annual royalty for a textbook I edited Greenfields Textbook of Surgery
Travel, Accommodations, Expenses - Konica Minolta Precision Medicine